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ABSTRACT
Long non-coding RNAs (lncRNAs) are deregulated in several tumors, although 
their role in acute myeloid leukemia (AML) is mostly unknown.
We have examined the expression of the lncRNA HOX antisense intergenic 
RNA myeloid 1 (HOTAIRM1) in 241 AML patients. We have correlated HOTAIRM1 
expression with a miRNA expression profile. We have also analyzed the prognostic 
value of HOTAIRM1 expression in 215 intermediate-risk AML (IR-AML) patients.
The lowest expression level was observed in acute promyelocytic leukemia 
(P < 0.001) and the highest in t(6;9) AML (P = 0.005). In 215 IR-AML patients, high 
HOTAIRM1 expression was independently associated with shorter overall survival 
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(OR:2.04;P = 0.001), shorter leukemia-free survival (OR:2.56; P < 0.001) and a 
higher cumulative incidence of relapse (OR:1.67; P = 0.046). Moreover, HOTAIRM1 
maintained its independent prognostic value within the favorable molecular subgroup 
(OR: 3.43; P = 0.009). Interestingly, HOTAIRM1 was overexpressed in NPM1-
mutated AML (P < 0.001) and within this group retained its prognostic value (OR: 
2.21; P = 0.01). Moreover, HOTAIRM1 expression was associated with a specific 
33- microRNA signature that included miR-196b (P < 0.001). miR-196b is located in 
the HOX genomic region and has previously been reported to have an independent 
prognostic value in AML. miR-196b and HOTAIRM1 in combination as a prognostic 
factor can classify patients as high-, intermediate-, or low-risk (5-year OS: 24% vs 
42% vs 70%; P = 0.004).
Determination of HOTAIRM1 level at diagnosis provided relevant prognostic 
information in IR-AML and allowed refinement of risk stratification based on 
common molecular markers. The prognostic information provided by HOTAIRM1 was 
strengthened when combined with miR-196b expression. Furthermore, HOTAIRM1 
correlated with a 33-miRNA signature.
INTRODUCTION
Acute myeloid leukemia (AML) is a highly 
heterogeneous disease, with diverse biological, phenotypic 
and prognostic behaviors and strikingly different outcomes 
to standard therapy. This prognostic diversity is most 
evident in the cytogenetic intermediate-risk AML subgroup 
(IR-AML), which is now commonly subdivided into 
molecular prognostic categories according to the mutational 
status of NPM1, internal tandem duplication of FLT3 
(FLT3-ITD), and CEBPA [1–3]. Although treatment of 
IR-AML patients is now tailored according to these 
molecular categories, the prognosis of many patients is still 
uncertain and the optimal post-remission therapy is unclear, 
indicating a clear need for additional prognostic markers.
In recent years, several studies of prognostic 
markers have focused on the role of RNA molecules 
that lack protein coding potential, known as non-coding 
RNAs (ncRNAs). Until recently, the majority of studies 
of ncRNAs in AML focused on microRNAs (miRNAs) 
and their roles in pathogenesis and prognosis [4–7], while 
long non-coding RNAs (lncRNAs, > 200 nt) have not been 
extensively studied. However, a recent study profiling 
lncRNAs found specific expression patterns associated 
with different AML categories and identified a 48-lncRNA 
score with prognostic implications in a subset of older 
patients with normal karyotype AML [8].
HOX genes play a key role in hematopoiesis [9] and 
leukemogenesis [10–13] and their expression level has been 
associated with prognosis in some AML subtypes [14–16]. 
Maintenance of HOX expression patterns is under complex 
epigenetic regulation and numerous ncRNAs, including 
lncRNAs, may participate in the regulation of HOX 
expression [17]. For example, HOTAIR, a lncRNA located 
in the genomic region of HOXC, regulates the expression 
of several HOX genes [17]. HOTAIR cooperates with miR-
196a (also located in the HOX genomic regions) to drive 
malignancy in gastric tumors [18]. The lncRNA HOTTIP, 
located in the region adjacent to the HOXA locus, is essential 
for the coordination of several 5′ HOXA genes [19] and 
the expression levels of HOTTIP and HOXA13 have been 
associated with progression in hepatocarcinoma [20].
lncRNAs transcribed in the intergenic regions, known 
as long intergenic non-coding RNAs (lincRNAs) [21], are 
dynamically expressed in hematopoiesis [22] and cancer 
[23]. HOTAIRM1 (HOX antisense intergenic RNA myeloid 1) 
is a lincRNA located in the HOXA genomic cluster, on 
chromosome band 7p15 between HOXA1 and HOXA2. 
HOTAIRM1 is transcribed antisense by RNA polymerase 
II. HOTAIRM1 expression is induced by retinoic acid and 
modulates the expression of genes involved in myeloid 
differentiation. It interacts with proteins of the Polycomb 
repressive complex2 in mouse embryonic stem cells [24]. 
HOTAIRM1 is overexpressed in myeloid leukemia cell lines 
and mature leukocytes compared to hematopoietic stem and 
progenitor cells [25]. However, HOTAIRM1 expression and 
its prognostic impact in AML patients have not yet been 
investigated.
In the present study, we have analyzed HOTAIRM1 
expression in a large cohort of AML patients (n = 241) 
with several cytogenetic subtypes. We have also explored 
its potential prognostic value in a subset of 215 IR-AML 
patients included in intensive therapy protocols for 
younger patients. Finally, we have examined the potential 
association between HOTAIRM1 and a miRNA profile.
RESULTS
HOTAIRM1 expression and clinical, cytogenetic 
and molecular characteristics
A significant difference in HOTAIRM1 expression 
level was observed among the five AML genetic 
subgroups included in the study and the healthy controls 
(ANOVA P < 0.001) (Figure 1a). The lowest HOTAIRM1 
levels were observed in APL patients (P < 0.001) 
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(Figure 1b), whereas the highest levels were in patients 
with t(6;9) AML (P = 0.005) (Figure 1c). HOTAIRM1 
expression levels were diverse in IR-AML patients 
(median, −1.49; range, −3.27 to 1.16). This information 
is shown in Figure 1d. Among IR-AML patients the 
highest levels were observed in those harboring NPM1 
mutations (NPM1mut patients) (P < 0.001) (Figure 1e). 
HOTAIRM1 expression was not significantly associated 
with any other mutations (DNMT3A, IDH1 or IDH2) or 
any clinical features, including age, WBC, bone marrow 
blast proportion, or FAB subtype.
We validated these results using arrays from 
the Leukemia-gene Atlas repository (http://www.
leukemia-gene-atlas.org/LGAtlas), an in silico analysis 
of HOTAIRM1 levels in different AML subgroups showed 
that in other cohorts [26, 27], HOTAIRM1 was also 
expressed at the lowest levels in APL and at the highest 
in t(6;9) AML (Supplementary Figure S1a). Similar to 
our findings, HOTAIRM1 expression was also higher in 
NPM1mut patients (Supplementary Figures S1b–S1c).
Higher HOTAIRM1 expression associated with 
worse prognosis in IR-AML
With a median follow-up of 7.6 years (range: 
15–196 months) among patients alive at last follow-up, the 
215 IR-AML patients had a CR rate of 80% and a 5-year 
OS, LFS, and CIR of 42 ± 6%, 42 ± 7%, and 44 ± 7%, 
respectively. Figure 1d shows the optimal cutoff level for 
HOTAIRM1 expression within the IR-AML as identified 
by the MaxStat package. Patients with higher HOTAIRM1 
levels had shorter OS and LFS (5-year OS: 23 ± 11% 
vs. 46 ± 7%, P = 0.001; LFS: 17 ± 12% vs.49 ± 8%, 
P < 0.001), and a higher CIR (57 ± 13% vs. 39 ± 8%, 
P = 0.043) compared to patients with lower levels 
(Figures  2a–2c). HOTAIRM1 expression levels were not 
Figure 1: HOTAIRM1 expression levels in AML patients and healthy controls. a. Expression levels of HOTAIRM1 varied 
among the five AML cytogenetic subtypes included in the study, namely cytogenetic intermediate-risk AML (IR-AML), AML with core-
binding factor rearrangement (CBF-AML), Acute Promyelocytic leukemia (APL), AML with translocation t(6;9)(p23;q34)/DEK-NUP214 
(t(6;9) AML), and monosomal karyotype AML. b. HOTAIRM1 expression was lower in APL than in the other AML subtypes. c. HOTAIRM1 
expression was higher in t(6;9) AML than in the other AML subtypes. d. The range of HOTAIRM1 expression levels among IR-AML 
samples, with the cutoff value identified by MaxStat package of R software as having the maximum prognostic impact. e.  Within the  
IR-AML subtype, HOTAIRM1 expression was higher in patients with NPM1 mutations. 
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Figure 2: Outcome according to HOTAIRM1 expression levels in IR-AML. High HOTAIRM1 expression was associated with 
poorer outcome in 215 IR-AML patients, with a. shorter overall survival, b. shorter leukemia-free survival, and c. a higher cumulative 
incidence of relapse.
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associated with the probability of attaining CR. Moreover, 
the frequency of allogeneic hematopoietic stem-cell 
transplantations (alloHSCT) performed in first CR (CR1) 
did not differ according to HOTAIRM1 expression levels 
(21% vs. 20.8% in patients with high and low HOTAIRM1 
levels, respectively, p = 0.99).
The multivariate analysis confirmed high 
HOTAIRM1 expression as an independent prognostic 
factor for OS (OR: 2.04; 95%CI:1.36–3.07; P = 0.001), 
LFS (OR: 2.56; 95%CI:1.67–3.92; P < 0.001) and CIR 
(OR:1.67; 95%CI:1.01–2.77; P = 0.04), in addition to 
age (OS, LFS), gender (LFS), WBC count at diagnosis 
(OS), presence of FLT3-ITD (OS, LFS, CIR), and NPM1 
mutations (OS, LFS, CIR) (Table 1).
We validated our findings on the prognostic value of 
HOTAIRM1 expression in another patient population [28] 
by performing an in silico re-analysis of the array data, 
available in the Leukemia-gene Atlas repository (http://
www.leukemia-gene-atlas.org/LGAtlas; Supplementary 
Figure S1d)
Higher HOTAIRM1 expression associated with 
worse prognosis in NPM1mut patients
Since HOTAIRM1 levels were significantly higher in 
NPM1mut patients (Figure 1e), we analyzed the prognostic 
value of HOTAIRM1 in this subset of patients. Since FLT3-
ITD is one of the most frequent mutations associated with 
NPM1 and its presence modifies the prognostic significance 
of NPM1, we compared HOTAIRM1 expression in patients 
with only NPM1 mutations with those with both NPM1 and 
FLT3-ITD mutations and we did not find any significant 
difference between both subgroups. Thus, the median value 
of HOTAIRM1 expression in patients with concomitant 
FLT3-ITD mutations was 1.32, and 1.18 in patients without 
FLT3-ITD mutations (p = 0.12). Among the 99 NPM1mut 
patients, those with high levels of HOTAIRM1 had shorter 
OS (5-year OS: 27 ± 14% vs. 61 ± 27%; P = 0.001) and 
LFS (5-year LFS: 22 ± 16% vs. 62 ± 12%; P < 0.001) and a 
higher CIR (5-year CIR: 58 ± 12% vs. 28 ± 9%; P = 0.003) 
(Figure 3a–3c). In the multivariate analyses including only 
NPM1mut patients, HOTAIRM1 expression retained its 
prognostic value for OS (OR: 2.21; 95%CI: 1.18–4.16; 
P = 0.014), LFS (OR: 2.84; 95% CI: 1.51–5.34; P = 0.001) 
and CIR (OR: 2.578; 95% CI: 1.245–5.33; P = 0.01) 
(Table 1). Other independent prognostic factors for the 
NPM1mut patients were age (OS, LFS, trend for CIR), WBC 
at diagnosis (OS), and FLT3-ITD (OS, CIR, trend for LFS).
Higher HOTAIRM1 expression associated with 
worse prognosis in the FAVmol subgroup
When we analyzed the specific impact of 
HOTAIRM1 expression on outcome in the molecularly 
defined subgroups (FAVmol and UNFAVmol), among the 
68 patients in the FAVmol subgroup, high HOTAIRM1 
expression identified a subset of patients with shorter 
OS (5-yr OS: 33 ± 20% vs.77 ± 10%; P = 0.004) and 
LFS (5-year LFS:18 ± 20% vs.74 ± 11%; P < 0.001) 
and a higher CIR (5-yr CIR: 54 ± 13% vs. 16 ± 10%; 
P = 0.008) (Figures 3d–3f). In the multivariate analyses, 
HOTAIRM1 expression retained its prognostic value in the 
FAVmol subgroup for OS (OR: 3.43; 95%CI: 1.37–8.61; 
P = 0.009), LFS (OR: 4.64; 95%CI: 1.93–11.1; P = 0.001), 
and CIR (OR: 3.863; 95%CI: 1.41–10.6; P = 0.008) 
(Table 1).
Among the 147 patients in the UNFAVmol 
subgroup, high levels of HOTAIRM1 were associated 
with shorter LFS (5-year LFS: 17 ± 13% vs. 31 ± 10%; 
P = 0.014) (Supplementary Figure S2) but not with OS 
or CIR.
Correlation of HOTAIRM1 with miRNA 
expression
Based on our previous comprehensive analysis 
of miRNA expression in 85 patients of the present 
series [5], we were able to identify a 33-miRNA 
signature which correlated with HOTAIRM1 expression 
(Table 2). This signature included the overexpression 
of several miRNAs located within the genomic regions 
of HOX gene clusters, including miR-196b (P < 0.001, 
correlation coefficient  [CC] = 0.41), miR-10a (P = 0.001, 
CC = 0.33), and miR-10a* (P = 0.003, CC = 0.35). In 
addition, the signature included other miRNAs involved 
in hematopoiesis and leukemogenesis, such as miR-9 
(P = 0.005, CC = 0.31), miR-222 (P = 0.005, CC = -0.32) 
and miR-424 (P = 0.009, CC = –0.30) (Table 2).
miR-196b, which showed the most significant 
association with HOTAIRM1, is located in the distal 
region of the same HOXA genomic region (Figure 4a). We 
therefore analyzed the correlation between miR-196b and 
HOTAIRM1 in the 215 IR-AML patients and found that 
high levels of HOTAIRM1 were significantly associated 
with high levels of miR-196b (P < 0.001) (Figure 4b).
The combination of HOTAIRM1 and miR-196b 
expression as a prognostic factor in IR-AML
Given the prognostic value of miR-196b 
expression identified in our previous work [6], the 
prognostic value of HOTAIRM1 expression identified 
in the present study, and the correlation between miR-
196b and HOTAIRM1, we performed a multivariate 
analysis for OS including miR-196b and HOTAIRM1 
expression, as well as other recognized prognostic 
markers (age, gender, WBC, mutational status of 
NPM1 and FLT3-ITD). Both miR-196b (OR: 2.36; 95% 
CI: 1.11–5; P = 0.026) and HOTAIRM1 (OR: 1.84; 95% 
CI: 1.23–2.78; P = 0.003) retained their independent 
prognostic significance.
We then constructed a risk score based on the 
effect of these two factors in combination in order to 
identify prognostic subgroups of IR-AML patients. 
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Table 1: Multivariate analyses for overall survival, leukemia-free survival, and cumulative 
incidence of relapse in the overall series, in patients with NPM1 mutations (NPM1mut patients), 
and in the favorable molecular category (i.e., NPM1 mutation without concomitant FLT3-ITD 
or CEBPA double mutation), within the cytogenetic intermediate-risk cohort. Age was analyzed 
with 10-year intervals and white blood cell count at diagnosis using 50 × 109/L increments
Variables P OR 95%CI P OR 95%CI P OR 95%CI
Overall Survival
All patients NPM1mut AML Favorable molecular category
Age <0.001 1.56 1.34–1.83 <0.001 1.83 1.36–2.48 0.02 1.60 1.07–2.39
Sex (male 
vs. female) 0.076 1.38 0.96–1.99 0.3 0.6
WBC 0.008 1.17 1.03–1.32 0.01 1.26 1.05–1.50 0.01 1.49 1.10–2.01
FLT3-ITD 0.002 1.88 1.27–2.79 0.01 2.07 1.13–3.81
NPM1 
mutations <0.001 0.45 0.31–0.67
HOTAIRM1 
levels (high 
vs. low)
0.001 2.04 1.36–3.07 0.01 2.21 1.18–4.16 0.009 3.43 1.36–8.61
Leukemia-Free Survival
All patients NPM1mut AML Favorable molecular category
Age 0.001 1.31 1.11–1.53 0.008 1.44 1.10–1.89 0.53
Sex (male 
vs. female) 0.024 1.57 1.06–2.33 0.5 0.92
WBC 0.2 1.08 0.95–1.23 0.19 0.08
FLT3-ITD 0.05 1.55 1.00–2.41 0.08 1.7 0.29–3.10
NPM1 
mutations 0.001 0.48 0.31–0.73
HOTAIRM1 
levels (high 
vs. low)
<0.001 2.56 1.67–3.92 0.001 2.84 1.51–5.34 0.001 4.64 1.93–11.16
Cumulative Incidence of Relapse
All patients NPM1mut AML Favorable molecular category
Age 0.28 0.07 0.06
Sex (male 
vs. female) 0.12 0.9 0.47
WBC 0.42 0.48 0.8
FLT3-ITD 0.02 1.72 1.06–2.78 0.0042 2.07 1.02–4.17
NPM1 
mutations 0.004 0.32 0.005–0.81
HOTAIRM1 
levels (high 
vs. low)
0.046 1.67 1.01–2.77 0.011 2.58 1.24–5.33 0.008 3.86 1.40–10.6
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Figure 3: Outcome according to HOTAIRM1 expression levels in (a–c) NPM1mut IR-AML patients and (d–f) patients 
in the FAVmol subgroup of IR-AML patients. a. overall survival, b. leukemia-free survival, and c. cumulative incidence of relapse 
in NPM1mut patients. d. overall survival, e. leukemia-free survival, and f. cumulative incidence of relapse in patients in the FAVmol 
subgroup.
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High miR-196b and high HOTAIRM1 expression 
were defined as high-risk factors. Patients were 
classified into three groups according to the number 
of high-risk factors: low-risk group, 0 factors; 
intermediate-risk group, 1 factor; and high-risk group, 
2 factors. Five-year OS for the low-, intermediate-, and 
high-risk groups was 70 ± 19%, 42 ± 8%, and 24 ± 12%, 
respectively (P = 0.004) (Figure 4c). Five-year LFS for 
the low-, intermediate-, and high-risk groups was 68 ± 
20%, 47 ± 8%, and 18 ± 12%, respectively (P < 0.001) 
Table 2: Thirty-three miRNAs whose expression correlated with HOTAIRM1 expression
Correlation coefficient Parametric p-value miRNA
0.412 <0.001 hsa-miR-196b
0.37 0.001 hsa-miR-27a*
0.364 0.001 hsa-miR-34a*
0.3662 0.001 hsa-miR-15b*
0.353 0.001 hsa-miR-10a*
0.347 0.002 hsa-miR-100*
0.342 0.002 hsa-miR-604
0.34 0.002 hsa-miR-641
0.338 0.002 hsa-miR-596
0.333 0.003 hsa-miR-487b
0.333 0.003 hsa-miR-519b
0.333 0.003 hsa-miR-10a
0.33 0.003 hsa-miR-339–5p
0.322 0.004 hsa-miR-188–5p
−0.319 0.005 hsa-miR-222
0.319 0.005 hsa-miR-606
0.316 0.005 hsa-miR-9
0.315 0.005 hsa-miR-519a
0.314 0.005 hsa-miR-520c-3p
0.308 0.006 hsa-miR-610
0.302 0.008 hsa-miR-9*
0.302 0.008 hsa-miR-650
0.301 0.008 hsa-miR-939
0.299 0.008 hsa-miR-580
0.299 0.008 hsa-miR-661
−0.299 0.008 hsa-miR-450b-5p
0.299 0.008 hsa-miR-760
0.299 0.009 hsa-miR-138–1*
0.298 0.009 hsa-miR-433
−0.297 0.009 hsa-miR-424
0.297 0.009 hsa-miR-155*
0.297 0.009 hsa-miR-605
0.297 0.009 hsa-miR-877
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(Supplementary Figure  S3a). A non-significant trend 
towards an effect on 5-year CIR was also observed 
(P = 0.08) (Supplementary Figure S3b).
Interestingly, this miR-196b/HOTAIRM1 combination 
showed a prognostic impact in the FAVmol subgroup, with 
5-year OS for the low-, intermediate- and high-risk groups of 
92 ± 16%, 71 ± 12, and 36 ± 29%, respectively (P = 0.016) 
(Figure 4d). Five-year LFS for the low-, intermediate-, and 
high-risk groups was 88 ± 20%, 70 ± 14%, and 20 ± 22%, 
respectively (P = 0.001) (Supplementary Figure S3c). 
No association with CIR was observed (Supplementary 
Figure S3d).
Among the NPM1mut patients, only two were 
classified as low-risk and were not included in the analysis. 
However, when high-risk patients were compared with 
intermediate-risk patients, high-risk patients had a shorter 
5-year OS (28 ± 16% vs.60 ± 12%, P = 0.003), shorter 
5-year LFS (24 ± 16% vs.61 ± 12%, P < 0.001), and a 
higher 5-year CIR (56 ± 19% vs.29 ± 11%, P < 0.001) 
(Supplementary Figures S4a–S4c).
The multivariate analyses for OS, LFS and CIR 
confirmed the miR-196b/HOTAIRM1 combination as 
an independent prognostic marker in the entire cohort, 
in NPM1mut patients, and in the FAVmol subgroup 
(Supplementary Table S1).
DISCUSSION
The present study, performed in 241 AML patients, 
has shown that lincRNA HOTAIRM1, located in the 
HOXA gene region, is differentially expressed in AML 
cells depending on the AML subtype. Interestingly, 
in 215 patients with IR-AML who received intensive 
chemotherapy, HOTAIRM1 provided independent 
prognostic information. High HOTAIRM1 expression 
identified a subset of patients with worse outcome both 
in the overall series of 215 IR-AML patients and within 
molecular prognostic categories as defined by NPM1, 
FLT3-ITD and CEBPA mutational status. To the best of 
our knowledge, this is the first time that a lincRNA has 
been identified as an independent prognostic factor in 
a large series of intensively treated IR-AML patients. 
Our findings suggest that a deregulated expression of 
HOTAIRM1 might play a role in AML leukemogenesis 
and outcome.
Although our study included only 26 non-IR-AML 
patients, interestingly, HOTAIRM1 expression differed 
among the five AML cytogenetic subgroups analyzed in 
our study, with the lowest levels in APL and the highest 
in t(6;9) AML. Among IR-AML patients, HOTAIRM1 
expression was significantly higher in NPM1mut patients. 
Figure 4: (a–b) Correlation between HOTAIRM1 and miR-196b. (c–d) Prognostic value of the combined expression 
of HOTAIRM1 and miR-196b. a. Genomic location of HOTAIRM1 and miR-196b at the Chr7(p15.2). b. Levels of HOTAIRM1 
according to miR-196b expression. c–d. Overall survival according to the risk score based on the expression of both HOTAIRM1 and 
miR-196b (c) in 215 IR-AML patients and (d) in patients in the FAVmol subgroup.
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When we validated these results using arrays from the 
Leukemia-gene Atlas repository (http://www.leukemia-
gene-atlas.org/LGAtlas), an in silico analysis of 
HOTAIRM1 levels in different AML subgroups showed 
that in other cohorts [26, 27], HOTAIRM1 was also 
expressed at the lowest levels in APL and at the highest 
in t(6;9) AML (Supplementary Figure S1a). Similar to 
our findings, HOTAIRM1 expression was also higher in 
NPM1mut patients (Supplementary Figures S1b–S1c).
HOX clusters have a specific pattern of lineage-
restricted expression, where HOXA genes are 
predominantly expressed in myeloid cells [29]. Moreover, 
HOXA genes are deregulated in several AML subtypes. 
HOXA gene cluster is downregulated in APL [30], which 
is in line with our findings on HOTAIRM1, and in CEBPA-
mutated patients [31]. In contrast, upregulation of some 
genes of the HOXA cluster has been observed in MLL-
AML [32], MYST3-CREBBP AML [33], NUP98-fusion 
gene AML [34, 35], and NPM1mut AML [14, 36, 37], 
which is in line with our results. HOTAIRM1 expression 
in our study parallels that reported for some HOXA genes 
in previous studies in APL and NPM1mut AML, lending 
support to the proposal by Sessa et al that the intergenic 
non-coding transcription of the HOX genomic regions 
may be crucial to maintaining the active state of HOX 
clusters [38].
In the present study, the highest levels of 
HOTAIRM1 expression were found in t(6;9) (p22;q34) 
DEK/NUP214 AML. HOXA gene upregulation has 
previously been described in SET-NUP 214 leukemia [29], 
another NUP214-fusion gene leukemia, through binding to 
HOXA promoters. This binding facilitates the recruitment 
of DOTL1, which in turn activates the transcription 
of some members of the HOXA cluster [39]. Given the 
similarities between DEK-NUP214 and SET-NUP214 
fusion proteins, both of which retain the CC and GLFG 
domains of NUP214 and also exhibit a similar gene-
expression profile [39], it is likely that DEK-NUP214 
functions in a similar fashion to SET-NUP214, namely by 
binding to the promoter regions of specific HOXA genes, 
which ultimately results in HOTAIRM1 overexpression.
Overexpression of HOTAIRM1 was independently 
associated with worse outcome in the entire series of 
215 IR-AML patients, with shorter OS (P = 0.001) and 
LFS (P < 0.001) and higher CIR (P = 0.04). Moreover, we 
confirmed the prognostic value of HOTAIRM1 expression 
in patients in the FAVmol subgroup (with NPM1 or CEBPA 
mutations but without FLT3-ITD mutations, defined as 
favorable in the ELN classification [1]). In addition, since 
HOTAIRM1 expression was particularly high in NPM1mut 
patients, we analyzed its prognostic value in these 
patients and were able to confirm its prognostic value, 
independently of additional features such as FLT3-ITD. 
Patients in the FAVmol subgroup or NPM1mut patients are 
not usually considered as candidates for alloHSCT in first 
CR, although approximately one-third of these patients 
will experience relapse after high-dose cytarabine-based 
post-remission frontline therapy. The identification of 
a high-risk subset among these patients could thus be 
useful in determining post-remission management [40], 
and the analysis of HOTAIRM1 expression may well 
be an additional tool for refining prognosis based on 
mutational status. Patients identified as being at high risk 
of relapse based on HOTAIRM1 expression could then 
be monitored closely to detect minimal residual disease 
and could be considered candidates for alloHSCT in first 
CR if MRD clearance kinetics confirmed this higher risk. 
In the UNFAVmol subgroup of patients (with FLT3-ITD 
mutations or without NPM1 or CEBPA mutations, defined 
as intermediate-1 and intermediate-2 in ELN classification 
[1]), HOTAIRM1 overexpression was associated with 
shorter LFS, but with no difference in OS.
We validated our findings on the prognostic value of 
HOTAIRM1 expression in another patient population [28] 
by performing an in silico re-analysis of the array data, 
available in the Leukemia-gene Atlas repository (http://
www.leukemia-gene-atlas.org/LGAtlas; Figure S1d). 
These results are in line with those of a previous 
analysis of array data in astrocytoma, which showed that 
HOTAIRM1 overexpression is associated with a more 
aggressive grade [41].
A complex regulatory interaction between lncRNAs, 
mRNAs and miRNAs has been described [42, 43] 
and lncRNAs seem to regulate both the expression 
of neighboring genes and distant genomic sequences 
[44]. Moreover, HOX genomic regions have numerous 
ncRNAs, suggesting that these ncRNAs may participate 
in the regulation of HOX expression [17]. Specifically, 
HOTAIRM1 quantitatively impairs expression of HOXA1 
and HOXA4 [25]. In addition, HOTAIRM1 regulates cell 
cycle progression during myeloid maturation in the NB4 
human promyelocytic leukemia cell line [45].
We also found that HOTAIRM1 expression was 
significantly associated with a 33-miRNA signature. 
The strongest association was with miR-196b, located 
in the distal part of the same HOXA cluster. Since our 
group had previously observed that miR-196b expression 
has prognostic value in IR-AML [6], we included this 
variable in a multivariate analysis and confirmed that both 
miR-196b and HOTAIRM1 retained their independent 
prognostic significance. Moreover, the combination of 
HOTAIRM1/miR-196b expression yielded a simple risk 
score which enabled IR-AML patients to be classified in 
three prognostic groups; in fact, the risk score also had an 
impact in the FAVmol subgroup. Along these same lines, 
cooperation between the lncRNA HOTAIR and miR-196a, 
both located within the HOXC cluster, has previously been 
described in gastric cancer, where both had prognostic 
value and the upregulation of both increased malignancy 
[18]. Indeed, the putative functional cooperation of the 
Oncotarget31623www.impactjournals.com/oncotarget
two ncRNAs, miR-196b and HOTAIRM1, in normal 
hematopoiesis and leukemia merits further investigation.
Two other miRNAs in the 33-miRNA signature – 
miR-10a and miR-10a*, contained within the HOXB gene 
cluster – also correlated with HOTAIRM1 expression. In 
addition, the signature includes other miRNAs involved 
in normal hematopoiesis and deregulated in AML, 
such as miR-9 [46], miR-222 [47], and miR-424 [47]. 
Interestingly, miR-424 and HOTAIRM1 were inversely 
correlated. Upregulation of miR-424 is involved in 
monocyte differentiation through miR-424-dependent 
translational repression of NFI-A [48], while HOTAIRM1 
is upregulated during myeloid differentiation but not 
during monocytosis [25]. Finally, the study of the putative 
pathways regulated by this HOTAIRM1-miRNA signature 
was performed using miR-Path [49] identified signaling 
pathways deregulated in AML included those signalized 
by c-KIT and FLT3 (Supplementary Figure S5).
In summary, HOTAIRM1 expression was observed 
in a molecular subtype-dependent manner and seems to 
parallel some HOXA expression. Moreover, determination 
of HOTAIRM1 level at diagnosis provided relevant 
prognostic information in a large series of IR-AML 
patients and allowed refinement of risk stratification 
based on common molecular markers. This additional 
prognostic information provided by HOTAIRM1 
expression was strengthened when combined with 
miR-196b expression. Furthermore, HOTAIRM1 correlated 
with a 33-miRNA signature containing several miRNAs 
with a role in normal hematopoiesis and leukemogenesis, 
including miR-196b. Taken together, these findings 
indicate that future functional studies of HOTAIRM1 are 
warranted to elucidate its role in AML and its impact on 
the aggressiveness of the disease.
MATERIALS AND METHODS
Patients and treatment
The analysis of HOTAIRM1 expression was 
performed in diagnostic samples from 241 patients 
diagnosed with de novo AML from the Cooperative 
Spanish group CETLAM. According to the MRC 
classification [2], 215 were IR-AML. The main 
characteristics of all patients are summarized in Table 3. 
In addition, mRNA from bone marrow samples from 
four healthy individuals was included in the study. All 
patients and controls provided their written informed 
consent in accordance with the Declaration of Helsinki, 
and the Ethics Committee of Hospital Clinic of Barcelona 
approved the study.
All 215 IR-AML patients were treated from 
1994 to 2009 in three consecutive CETLAM trials of 
intensive chemotherapy for fit patients: AML-94 (n = 10); 
AML-99 (n = 31) (NCT01716793); AML-03 (n = 174) 
(NCT01723657). Briefly, the induction regimen of 
AML-94 was ICE (idarubicin, standard-dose cytarabine, 
and etoposide), while in AML-99 and AML-03 it consisted 
of one or two courses of IDICE (idarubicin, intermediate-
dose cytarabine, and VP-16), with or without priming 
with G-CSF. All patients achieving complete remission 
(CR) received an additional course of chemotherapy 
with mitoxantrone and high-dose cytarabine, and then 
a transplant decision was made. In protocols AML-99 
and AML-03, an autologous hematopoietic stem-cell 
transplantation (autoHSCT) was planned for patients 
harboring a normal karyotype without additional risk 
factors, whereas an allogeneic HSCT (alloHSCT) in first 
CR (CR1) was recommended for the remaining patients 
with an available donor. Risk factors considered for risk 
assignment were the need for two induction courses to 
achieve CR, detectable minimal residual disease (MRD) 
by flow cytometry (AML-03), and presence of FLT3-
ITD (AML-03). In AML-94, post-remission strategy 
(autoHSCT vs. alloHSCT) depended exclusively on the 
availability of an HLA-identical sibling.
RNA extraction
Samples were obtained from bone marrow aspirates 
in 232 (96%) patients and from peripheral blood, with 
a minimum blast infiltration of 80%, in the remaining 
9 patients. Mononuclear cells were purified by Ficoll 
density gradient centrifugation and total RNA was isolated 
using Trizol reagent according to manufacturer’s protocol 
(Invitrogen, Paisley, UK).
mRNA expression analysis
cDNA was synthesized from 1000 nanograms 
of total RNA using TaqMan Reverse Transcription 
Reagent Kit (Applied Biosystems). Real-time PCR was 
performed in the ABI Prism 7500 Sequence Detection 
System (Applied Biosystems) using TaqMan Gene 
expression assays (Applied Biosystems) to determine 
mRNA levels of HOTAIRM1 (Hs03296533_g1) 
and GUSB(Hs00939627_m1). All gene expression 
determinations were run in triplicate. Relative 
quantification was calculated using the 2−ΔCt method 
using GUSB as housekeeping gene.
miRNA quantification
HOTAIRM1 level was correlated with miRNA 
expression data obtained in previous studies by our group 
[5, 6]. Briefly, in these studies, after first performing a 
comprehensive miRNA expression analysis of 670 mature 
human miRNAs in tumor samples from 85 IR-AML 
patients using TaqMan® Array Human MicroRNA Set 
Cards v2.0 (AB), we selected a group of ten miRNAs 
with potential prognostic value (miR-644, miR-196b, 
miR-409-3p, miR-135a, let-7a*, miR-23a*, miR-627, 
miR-200c, miR-23b and miR-361–3p). These miRNAs 
were subsequently analyzed by individual assays.
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Molecularly defined prognostic subgroups in 
IR-AML
The presence or absence of FLT3-ITD, NPM1 
and biallelic CEBPA mutations have a strong prognostic 
impact in patients with IR-AML [1, 3]. According to the 
European LeukemiaNet (ELN) prognostic classification, 
patients with the NPM1 mutation or the biallelic CEBPA 
mutation but without the FLT3-ITD mutation, when 
associated to normal cytogenetics, comprise a favorable 
genetic group – with better prognosis, while patients with 
the FLT3-ITD mutation and/or without the NPM1 and the 
biallelic CEBPA mutation comprise the intermediate-I and 
intermediate-II genetic groups. In the present study, we 
have classified all IR-AML patients with NPM1 mutations 
or biallelic CEBPA mutations but without FLT3-ITD 
Table 3: Main clinical characteristics of patients included in the study
Overall series n = 245
AML cytogenetic subtypes
 Core-binding factor-AML
  t(8;21)/RUNX1-RUNXT1
  inv(16)/t(16;16)/MYH11-CBFbeta AML
 Acute promyelocytic leukemia
 t(6;9)AML
 Monosomal karyotype1 AML
 Intermediate-risk AML
Bone marrow from healthy donors
5
3
2
4
10
7
215
4
Intermediate risk AML n = 215
Year of diagnosis (range) 1994–2009
Gender n (%)
 Male
 Female
114 (53%)
101 (47%)
Median age, years (range) 51 (17–71)
Leukocyte count at diagnosis, × 109/L median (range) 28 (0.7–408)
FAB subtype (n)
 M0
 M1
 M2
 M4
 M5
 M6
 M7
10
53
38
54
50
8
2
Cytogenetics n (%)
 Normal karyotype
 Other intermediate-risk
155 (72%)
60 (28%)
Molecular features n (%)
 NPM1 mutation
 FLT3-ITD
 CEBPA biallelic mutation
99/212 (41%)
75/214 (35%)
17/144 (11%)
Therapeutic protocol (CETLAM group)
 AML-94
 AML-99
 AML-2003
10 (4%)
31 (14%)
174 (82%)
Outcome
 Complete response to induction regimen
 Overall survival (5-yr)
 Leukemia-free survival (5-yr)
 Cumulative incidence of relapse (5-yr)
86%
42 ± 6%
42 ± 7%
44 ± 7%
1Defined according to Breems et al [53]
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mutations as the favorable molecular (FAVmol) subgroup 
and all remaining IR-AML patients as the unfavorable 
molecular (UNFAVmol) subgroup.
Clinical endpoints and statistical methods
Overall survival (OS) was calculated from 
diagnosis to death and leukemia-free survival (LFS) from 
CR to relapse or death. Both OS and LFS were estimated 
with the Kaplan-Meier method and comparisons among 
subgroups of patients were performed using the log-
rank test. Relapse risk (RR) was calculated from CR to 
relapse and estimated using the cumulative incidence 
of relapse (CIR) method computed with the cmprsk 
package for R 2.12 software. The competing event in 
the RR analysis was death without relapse. Comparison 
of RR between groups of patients was performed using 
the Gray test [50]. Characteristics between groups were 
compared using the χ2 test and Fisher’s exact test, when 
applicable, for categorical variables, and the t-test for 
continuous variables. Multivariate analyses for OS 
and LFS were performed using the Cox proportional 
hazards model including age (10-year intervals), gender, 
white blood cell count (WBC; 50 × 109/L increments) 
at diagnosis, mutational status of NPM1 and FLT3-
ITD, and HOTAIRM1 expression level. A multivariate 
analysis for CIR was performed using the subdistribution 
regression model of Fine and Gray [51] with the cmprsk 
package. The proportional hazard assumption was tested 
for each variable by analyzing the Schoenfeld residuals. 
Kaplan-Meier survival curves were then drawn for 
HOTAIRM1 expression predicted to show a survival 
risk either above or below average risk, using the cutoff 
points of HOTAIRM1 expression levels identified by 
MaxStat package of R software. All analyses were 
performed with SPSS v.20 or R software version 2.12.2. 
Significance was set at ≤ 0.05. For the identification 
of miRNAs significantly correlated with HOTAIRM1 
expression, we used data from our previously identified 
miRNA profile [5] and a quantitative trail analysis from 
BRB Array Tools version 3.5.0 [52] with adjustment for 
multiple comparisons.
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